First‐line PD‐1/PD‐L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non‐squamous non‐small cell lung cancer: A Bayesian network meta‐analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4589
Abstract: Chemotherapy in combination with immune checkpoint inhibitor (ICI) or bevacizumab has demonstrated a superior effect for non‐squamous non‐small cell lung cancer (NS‐NSCLC). There are still few randomized controlled trials (RCTs) investigating the differences between ICI… read more here.
Keywords: plus chemotherapy; ici chemotherapy; first line; bev chemotherapy ... See more keywords
Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5757
Abstract: Pembrolizumab plus chemotherapy improved progression‐free survival (PFS) and overall survival (OS) compared with placebo plus chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple‐negative breast cancer with tumor programmed cell death ligand… read more here.
Keywords: plus chemotherapy; pembrolizumab plus; triple negative; negative breast ... See more keywords
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34687
Abstract: BACKGROUND EMPOWER-Lung 3, a randomized 2:1 phase 3 trial, showed clinically meaningful and statistically significant overall survival improvement with cemiplimab plus platinum-doublet chemotherapy versus placebo plus chemotherapy for first-line treatment of advanced non-small cell lung cancer. This study evaluated… read more here.
Keywords: plus chemotherapy; cemiplimab plus; lung; chemotherapy ... See more keywords
First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34296
Abstract: First‐line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)‐negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; read more here.
Keywords: nivolumab plus; plus chemotherapy; first line; chinese patients ... See more keywords
Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer
Sign Up to like & getrecommendations! Published in 2021 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-021-06572-4
Abstract: Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors plus chemotherapy have become the standard first line of treatment in patients with advanced non-small-cell lung cancer (NSCLC). However, few studies have explicitly focused on the impact… read more here.
Keywords: plus chemotherapy; inhibitors plus; treatment; weight loss ... See more keywords
Cellular immunotherapy plus chemotherapy ameliorates survival in gastric cancer patients: a meta-analysis
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-020-01750-6
Abstract: The efficacy of cellular immunotherapy plus chemotherapy in treatment of gastric cancer (GC) remains inconsistent even controversial. Hence, we performed a meta-analysis to better comprehend the clinical value of cellular immunotherapy plus chemotherapy for GC… read more here.
Keywords: plus chemotherapy; cellular immunotherapy; immunotherapy; immunotherapy plus ... See more keywords
Anlotinib plus chemotherapy as first-line treatment for advanced ovarian cancer: a prospective, single-arm, single-center, phase II clinical study
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic Oncology"
DOI: 10.1016/s0090-8258(21)00811-8
Abstract: Objectives: Anlotinib is an oral multi-kinase inhibitor that widely inhibits VEGFR, PDGFR, FGFR and c-kit. Previous researches have shown clinical antitumor activity of anlotinib in various cancers, including the gynecologic tumors. This investigator-initiated, single-arm, open-label,… read more here.
Keywords: plus chemotherapy; treatment; anlotinib plus; ovarian cancer ... See more keywords
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Sign Up to like & getrecommendations! Published in 2020 at "The Lancet"
DOI: 10.1016/s0140-6736(20)31953-x
Abstract: BACKGROUND Preferred neoadjuvant regimens for early-stage triple-negative breast cancer (TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy. IMpassion031 compared efficacy and safety of atezolizumab versus placebo combined with nab-paclitaxel followed by doxorubicin plus cyclophosphamide as neoadjuvant treatment… read more here.
Keywords: chemotherapy; chemotherapy group; placebo; stage ... See more keywords
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Sign Up to like & getrecommendations! Published in 2021 at "The Lancet"
DOI: 10.1016/s0140-6736(21)00797-2
Abstract: BACKGROUND First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median overall survival (OS) of less than 1 year. We aimed to evaluate first-line… read more here.
Keywords: chemotherapy alone; gastro oesophageal; gastric gastro; plus chemotherapy ... See more keywords
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
Sign Up to like & getrecommendations! Published in 2022 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyac188
Abstract: Abstract Objective First-line pembrolizumab with/without chemotherapy versus chemotherapy was evaluated in programmed death ligand 1 combined positive score ≥1, locally advanced/unresectable or metastatic gastric cancer/gastrooesophageal junction cancer in the KEYNOTE-062 study. We present results for… read more here.
Keywords: plus chemotherapy; pembrolizumab plus; chemotherapy versus; pembrolizumab ... See more keywords
Anti‐PD‐1 therapy plus chemotherapy showed superior and durable survival benefit in a patient with small cell esophageal cancer: A case report
Sign Up to like & getrecommendations! Published in 2020 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13735
Abstract: The prognosis of the small cell esophageal cancer (SCEC) patient in our study was poor due to lack of treatment options which were limited to surgery and chemotherapies, with a median overall survival (OS) of… read more here.
Keywords: esophageal cancer; plus chemotherapy; cell esophageal; cancer ... See more keywords